Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Association of Fetal Exposure to Newer Antiseizure Medications With Neurodevelopment

Association of Fetal Exposure to Newer Antiseizure Medications With Neurodevelopment Opinion EDITORIAL Association of Fetal Exposure to Newer Antiseizure Medications With Neurodevelopment A Step Toward a Better Understanding Torbjörn Tomson, MD, PhD; Rebecca Bromley, ClinPsyD, PhD comes has been insufficient even for these frequently pre- The teratogenic risks of antiseizure medications (ASMs) have been a concern since the first reports more than 50 years ago scribed second-generation ASMs. The reason for this dis- of an association between maternal use of ASMs and occur- crepancy is that compared with birth defects, assessment of rence of birth defects in offspring. The risks and possible cognitive functions and other neurodevelopmental out- differences in risks between comes requires longer-term, expert follow-up and is there- ASMs have become a major fore demanding of resources. Related article factor in treatment decision It is in this context that we should read the Maternal Out- and in particular drug selection for girls and young women with comes and Neurodevelopmental Effects of Antiepileptic Drugs 2 15 epilepsy. Although the initial focus was on anatomical tera- (MONEAD) study by Meador et al in this issue of JAMA Neu- togenicity (ie, malformations), more attention has been given rology. The researchers behind the landmark Neurodevelop- during the last 2 decades to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Association of Fetal Exposure to Newer Antiseizure Medications With Neurodevelopment

JAMA Neurology , Volume 78 (8) – Aug 7, 2021

Loading next page...
 
/lp/american-medical-association/association-of-fetal-exposure-to-newer-antiseizure-medications-with-SoaW010nRF
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/jamaneurol.2021.1217
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Association of Fetal Exposure to Newer Antiseizure Medications With Neurodevelopment A Step Toward a Better Understanding Torbjörn Tomson, MD, PhD; Rebecca Bromley, ClinPsyD, PhD comes has been insufficient even for these frequently pre- The teratogenic risks of antiseizure medications (ASMs) have been a concern since the first reports more than 50 years ago scribed second-generation ASMs. The reason for this dis- of an association between maternal use of ASMs and occur- crepancy is that compared with birth defects, assessment of rence of birth defects in offspring. The risks and possible cognitive functions and other neurodevelopmental out- differences in risks between comes requires longer-term, expert follow-up and is there- ASMs have become a major fore demanding of resources. Related article factor in treatment decision It is in this context that we should read the Maternal Out- and in particular drug selection for girls and young women with comes and Neurodevelopmental Effects of Antiepileptic Drugs 2 15 epilepsy. Although the initial focus was on anatomical tera- (MONEAD) study by Meador et al in this issue of JAMA Neu- togenicity (ie, malformations), more attention has been given rology. The researchers behind the landmark Neurodevelop- during the last 2 decades to

Journal

JAMA NeurologyAmerican Medical Association

Published: Aug 7, 2021

References